Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

ASA404 (5,6-dimethylxanthenone-4-acetic acid or DMXAA) is a small-molecule tumour-vascular disrupting agent (Tumour-VDA). This randomised phase II study evaluated ASA404 plus standard therapy of carboplatin and paclitaxel in patients with histologically confirmed stage IIIb or IV non-small cell lung...

Descripción completa

Detalles Bibliográficos
Autores principales: McKeage, M J, Von Pawel, J, Reck, M, Jameson, M B, Rosenthal, M A, Sullivan, R, Gibbs, D, Mainwaring, P N, Serke, M, Lafitte, J-J, Chouaid, C, Freitag, L, Quoix, E
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2607218/
https://www.ncbi.nlm.nih.gov/pubmed/19078952
http://dx.doi.org/10.1038/sj.bjc.6604808

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2607218/
https://www.ncbi.nlm.nih.gov/pubmed/19078952
http://dx.doi.org/10.1038/sj.bjc.6604808

Ejemplares similares